Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

NCT01006551

Last updated date
Study Location
Harvard University
Medford, Massachusetts, 02155, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-19 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Between 6 and 19 years old, male or female.

- Significant psychotic symptoms defined by a behavior score of at least 4 (moderate) on at least one of the psychotic items of Positive and Negative Symptom Scale (PANSS) at baseline.

- Subjects will meet DSM IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder.

- Subjects will be free of depot antipsychotic medication for at least six months.

- Good physical health.

- The subject gives informed assent for the study and his/her guardian is able and willing to give informed consent.

- Mood stabilizing treatment (i.e., antidepressant, lithium, carbamazepine, valproate) will be permitted during the first eight weeks of the study only if the patient has been treated with the mood stabilizer for at least 30 days. Dosages will remain stable for the first 8 weeks unless change or discontinuation is clinically indicated.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- A primary diagnosis of substance abuse or dependence.


- Known endocrinological or neurological conditions, which confound the diagnosis or are
a contraindication to treatment with antipsychotics.


- Subjects with a clear history of intolerance or nonresponsiveness to ziprasidone.


- Subjects at serious, short term risk for suicide.


- Subjects who are pregnant or who refuse to practice contraception during the study.


- Subjects with known cardiac conduction problems especially prior QTc prolongation,
known genetic risk for QTc prolongation or who are being treated with other agents
that prolong the QTc. These agents include the antiarrhythmic agents: dofetilide
(Tkosyn), sotalol (Betapace), quinidine (Quinaglute), or Class 1A and III
antiarrhythmics; the antipsychotics mesoridazine (Serentil), thioridazine (Mellaril),
chlorpromazine (Thorazine), droperidol (Inapsine), pimozide (Orap); the
anti-infectives: sparfloxacin (Zagam), gatifloxacin (Tequin), moxifloxacin (Avelox),
pentamidine (Pentam); the anti-malarials halofantrine (Halfan), mefloquine (Lariam);
and arsenic trioxide (Trisenox), levomethadyl acetate (Orlaam), dolasetron mesylate
(Anzemet), probucol (Lorelco-an antilipemic), and tacrolimus (Prograf).


- Subjects with a diagnosis of a pervasive developmental disorder or an autism screening
questionnaire score >15, must have clear hallucinations or delusions.


- Subjects will be excluded if they meet criteria for a current major depressive
episode.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

SchizophreniaAdd On Treatment for Cognitive Deficits in Schizophrenia
NCT01346163
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
SchizophreniaThe Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
NCT02935998
  1. Beijing, Beijing
ALL GENDERS
18 Years+
years
MULTIPLE SITES
SchizophreniaZiprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
NCT00351000
  1. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
SchizophreniaEffects of Varenicline on Plasticity in Schizophrenia
NCT01934023
  1. Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
Official Title  ICMJE Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
Brief Summary This is an open trial of ziprasidone (ZIP) in children and adolescents. It is designed to provide pilot data on the magnitude of ZIP's antipsychotic effects in psychotic youth, dosing ranges, acute safety, and tolerability. This would then inform the design of a rigorous, randomized controlled trial of ZIP in the pediatric population. The primary study hypothesis is that the proportion of pediatric subjects responding to treatment with ziprasidone will be comparable or greater than reported in trials of ziprasidone in adults.
Detailed Description The study will consist of two phases: an eight week acute phase and a 44 week continuation phase for those subjects who show a response during the first eight weeks. All treatment will be open label and monitored by research clinicians with expertise in treating psychotic youth. The initial titration is relatively slow to minimize side effects. A flexible dose strategy in which each individual's ultimate dose is determined by his/her response and side effects will be used. The maximal dose will be 160mg split as a BID dose. We estimate that the average dose will be 120mg/d. Concurrent use of benztropine, propranolol, and benzodiazepines (lorazepam and clonazepam) will be permitted as needed to treat any emergent extrapyramidal side effects and agitation. Concurrent use of antidepressants and mood stabilizers will be permitted in those subjects who have been on stable doses of antidepressants or mood stabilizers for at least four weeks at time of entry, or those with emergence of significant affective symptoms during the maintenance phase of the study.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Schizophrenia
Intervention  ICMJE Drug: Ziprasidone
20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
Other Name: Geodon
Study Arms  ICMJE Experimental: Ziprasidone
Intervention: Drug: Ziprasidone
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 2, 2009)
40
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 2006
Actual Primary Completion Date February 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Between 6 and 19 years old, male or female.
  • Significant psychotic symptoms defined by a behavior score of at least 4 (moderate) on at least one of the psychotic items of Positive and Negative Symptom Scale (PANSS) at baseline.
  • Subjects will meet DSM IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder.
  • Subjects will be free of depot antipsychotic medication for at least six months.
  • Good physical health.
  • The subject gives informed assent for the study and his/her guardian is able and willing to give informed consent.
  • Mood stabilizing treatment (i.e., antidepressant, lithium, carbamazepine, valproate) will be permitted during the first eight weeks of the study only if the patient has been treated with the mood stabilizer for at least 30 days. Dosages will remain stable for the first 8 weeks unless change or discontinuation is clinically indicated.

Exclusion Criteria:

  • A primary diagnosis of substance abuse or dependence.
  • Known endocrinological or neurological conditions, which confound the diagnosis or are a contraindication to treatment with antipsychotics.
  • Subjects with a clear history of intolerance or nonresponsiveness to ziprasidone.
  • Subjects at serious, short term risk for suicide.
  • Subjects who are pregnant or who refuse to practice contraception during the study.
  • Subjects with known cardiac conduction problems especially prior QTc prolongation, known genetic risk for QTc prolongation or who are being treated with other agents that prolong the QTc. These agents include the antiarrhythmic agents: dofetilide (Tkosyn), sotalol (Betapace), quinidine (Quinaglute), or Class 1A and III antiarrhythmics; the antipsychotics mesoridazine (Serentil), thioridazine (Mellaril), chlorpromazine (Thorazine), droperidol (Inapsine), pimozide (Orap); the anti-infectives: sparfloxacin (Zagam), gatifloxacin (Tequin), moxifloxacin (Avelox), pentamidine (Pentam); the anti-malarials halofantrine (Halfan), mefloquine (Lariam); and arsenic trioxide (Trisenox), levomethadyl acetate (Orlaam), dolasetron mesylate (Anzemet), probucol (Lorelco-an antilipemic), and tacrolimus (Prograf).
  • Subjects with a diagnosis of a pervasive developmental disorder or an autism screening questionnaire score >15, must have clear hallucinations or delusions.
  • Subjects will be excluded if they meet criteria for a current major depressive episode.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 19 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01006551
Other Study ID Numbers  ICMJE 2002-0012
2002-0012
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Linmarie Sikich, MD, University of North Carolina, Chapel Hill
Study Sponsor  ICMJE University of North Carolina, Chapel Hill
Collaborators  ICMJE
  • Pfizer
  • National Institute of Mental Health (NIMH)
Investigators  ICMJE
Principal Investigator:Linmarie Sikich, MDUniversity of North Carolina, Chapel Hill
PRS Account University of North Carolina, Chapel Hill
Verification Date November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP